Meridian Bioscience Inc. (VIVO) is in the Pharma Industry

• Sort by

• ResMed Beats Earnings Estimates; Back on Track

  Robert Freedland submits: I am absolutely in love with Meridian Bioscience VIVO but with the latest quarter mildly disappointing, and the stock lagging while the rest of the market moves higher, I grew impatient yesterday and started looking for another vehicle for my investment purposes. Okay, it...

  External links 2008-08-07

  Tags: Biotech, ResMed Inc., Meridian Bioscience Inc.

Additional Resources

• Meridian Bioscience to Present at the 2008 UBS Global Life Science Conference

  CINCINNATI -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the 2008 UBS Global Life Science Conference at the Grand Hyatt New York in New York City. Jack Kraeutler, CEO, is scheduled to present on Wednesday, September 24, 2008 at...

  Articles 2008-09-23

• Vybion sells protein business to Ohio company

  ITHACA - Vybion, Inc, a local bio-technology company, sold part of its business in June to Meridian Bioscience, Inc. (NASDAQ: VIVO) of Cincinnati. Vybion sold its recombinant protein business to Meridian for $653,000. The business involved the production of proteins used in diagnostic medicine like blood testing. It's...

  Articles 2008-07-18

• Examine the World Peptic Ulcer Testing Market

  Reportlinker.com announces that a new market research report related to the Laboratory equipment industry is available in its catalogue. World Peptic Ulcer Testing Market http://www.reportlinker.com/p090666/World-Peptic-Ulcer-Testing-Market.html This report analyzes the worldwide markets for Peptic Ulcers Testing in Millions of US$. The report provides separate comprehensive...

  Articles 2008-07-07

• Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience, Inc

  ITHACA, N.Y. -- Vybion, Inc., an Ithaca-based biotechnology company, today announced that it has executed a letter of intent to sell its recombinant protein business to Meridian Bioscience, Inc. (NASDAQ: VIVO). The planned transaction, which both Vybion and Meridian expect will be completed within the next 60 days, calls for...

  Articles 2008-05-14

• Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins from Vybion, Inc

  CINCINNATI -- Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future royalties based on net sales of the acquired products, the...

  Articles 2008-05-13

• Meridian Bioscience to Present at the Robert W. Baird 2008 Growth Stock Conference

  CINCINNATI -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2008 Growth Stock Conference on Wednesday, May 14, 2008 at 3:05 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Executive Chairman of the Board and...

  Articles 2008-05-12

• Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results

  CINCINNATI -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: * reported record second quarter and six months net sales of $36.2 million and $70.1 million, respectively, increases of 13% and 15% over the same periods of...

  Articles 2008-04-17

• Meridian Bioscience Launches Two New TRU™ Brand Rapid Tests for the Detection of Epstein-Barr Virus

  CINCINNATI -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has launched two new rapid tests for Epstein-Barr Virus EBV: TRU EBV-M[TM] and TRU EBV-G[TM]. The TRU EBV tests are the first rapid tests on the market which employ recombinant antigen technology to detect IgM and IgG antibodies specific...

  Articles 2008-04-09

• Meridian Bioscience

  Meridian Bioscience promoted John A. Kraeutler, president and CO0, to CEO, replacing William J. Motto, who was named executive chairman...

  Articles 2008-03-31

• Meridian Bioscience Inc. Review in Progress.

  M2 PRESSWIRE-26 March 2008-MB Alerts: Meridian Bioscience Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:26032008 MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Investors wanting to know the truth about investing and...

  Articles 2008-03-26

• Meridian Bioscience Inc. Review in Progress.

  M2 PRESSWIRE-25 March 2008-Streetinvesting.com: Meridian Bioscience Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:25032008 Streetinvesting.com has now resumed our progressive review of Meridian Bioscience Inc. (NASDAQ:VIVO) as it opened up $0.13 on below average volume early trading Tuesday, March...

  Articles 2008-03-25

• Meridian Bioscience to Present at the Sidoti & Company, LLC Twelfth Annual New York Emerging Growth Institutional Investor Forum

  CINCINNATI -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Sidoti & Company, LLC Twelfth Annual New York Emerging Growth Institutional Investor Forum at The Hyatt Regency Hotel in New York. Jack Kraeutler, Chief Executive Officer, is scheduled to...

  Articles 2008-03-25

• Meridian Bioscience Inc Deals And Alliances Profile Is An Essential Source For Company Data And Information.

  M2 PRESSWIRE-12 March 2008-Research and Markets: Meridian Bioscience Inc Deals And Alliances Profile Is An Essential Source For Company Data And InformationC1994-2008 M2 COMMUNICATIONS LTD RDATE:12032008 Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c85712) has announced the addition of "Meridian...

  Articles 2008-03-12

• Meridian Bioscience Inc Deals and Alliances Profile is an Essential Source for Company Data and Information

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c85710) has announced the addition of "Meridian Bioscience, Inc. Deals and Alliances Profile" to their offering. Introduction Global Market Direct's Meridian Bioscience, Inc. Deals and Alliances Profile is an essential source for company data and information. The profile examines Meridian...

  Articles 2008-03-12

• Meridian Bioscience Promotes John A. Kraeutler to Chief Executive Officer, William J. Motto Moves to Executive Chairman

  CINCINNATI -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Board of Directors has appointed Jack Kraeutler to Chief Executive Officer. Mr. Kraeutler joined the Company in January, 1992 as Executive Vice President and Chief Operating Officer. In July 1992, Mr. Kraeutler was named President and Chief...

  Articles 2008-01-28

• Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2008 Guidance

  CINCINNATI -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: * reported record first quarter net sales of $33.8 million an 18% increase over the same period of the prior fiscal year; * reported record quarterly net...

  Articles 2008-01-22

• Elevated risk of carrying gentamicin-resistant Escherichia coli among U.S. poultry workers

  Antimicrobial-resistant bacteria including Escherichia coli are common contaminants of the industrial broiler chicken environment (Hayes et al. 2004; Khan et al. 2005). Studies conducted in Europe indicate that poultry growers and poultry-house workers are at risk of exposure to these and other pathogens (Ojeniyi 1989; van den...

  Articles 2007-12-01

• Meridian Bioscience Receives FDA Clearance for Two New Rapid Tests for the Detection of Influenza and Respiratory Syncytial Virus

  CINCINNATI -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration FDA to market two new upper respiratory tests: TRU FLU([R]) and TRU RSV([R]). These tests are based upon a new rapid test technology that features improved safety and space savings....

  Articles 2007-11-26

• Meridian Bioscience Reports Record Fiscal 2007 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance

  CINCINNATI -- Meridian Bioscience, Inc. GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: * reported record fourth quarter and full-year fiscal 2007 net sales of $32.4 million and $123.0 million, respectively, increases of 13% over the same periods of the...

  Articles 2007-11-14